Supplementary Figure S5 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Fig.S5: exPBNK cells tracking and persistence in vivo (A) exPBNK cells were labeled with DID and iv injected into NSG mice. 8 days later after NK injection, mice were sacrificed and organs (lung, liver, spleen, kidney, heart) and bones were collected and washed with D-PBS. Fluorescent imagings were acquired and analyzed by using LIVING IMAGE (Xenogen). (B) Single cell suspensions were obtained from lung, liver and spleen and analyzed by flow cytometry to detect DID labeled exPBNK cells. (C) 1x10*7 mock exPBNK or CAR exPBNK cells were IV injected to Raji-Luc xenografted mice through the tail veins. Peripheral blood was collected at the indicated time point after NK NK injection. Circulated NK cells from mock exPBNK group and CAR exPBNK group were quantified using the Trucount method by flow cytometry analysis with anti-CD56-PE antibodies.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362532394